Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Net Income towards Common Stockholders (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Net Income towards Common Stockholders readings, the most recent being -$23.2 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 134.55% to -$23.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$95.9 million through Dec 2025, down 61155.41% year-over-year, with the annual reading at -$95.9 million for FY2025, 61155.41% down from the prior year.
  • Net Income towards Common Stockholders hit -$23.2 million in Q4 2025 for Terns Pharmaceuticals, up from -$24.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $67.2 million in Q4 2024 and bottomed at -$29.8 million in Q3 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$12.3 million, with a median of -$19.5 million recorded in 2023.
  • The largest annual shift saw Net Income towards Common Stockholders soared 420.23% in 2021 before it crashed 144.48% in 2022.
  • Terns Pharmaceuticals' Net Income towards Common Stockholders stood at $35.6 million in 2021, then crashed by 144.48% to -$15.8 million in 2022, then crashed by 32.97% to -$21.0 million in 2023, then soared by 419.47% to $67.2 million in 2024, then plummeted by 134.55% to -$23.2 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Net Income towards Common Stockholders are -$23.2 million (Q4 2025), -$24.6 million (Q3 2025), and -$24.1 million (Q2 2025).